David R. Lynch, MD, PhD

faculty photo
Professor of Neurology
Department: Neurology
Graduate Group Affiliations

Contact information
502 Abramson Center
Children's Hospital of Philadelphia
Philadelphia, PA 19104
Office: 2155902242
Fax: 2155903779
Education:
B.S. (Molecular Biophysics and Biochemistry)
Yale College, 1981.
Ph.D. (Neuroscience)
Johns Hopkins University, 1988.
M.D. (Neuroscience)
Johns Hopkins University, 1988.
Permanent link
 

Description of Research Expertise

RESEARCH INTERESTS
NMDA receptors

KEY WORDS:
glutamate, receptor

RESEARCH TECHNIQUES
Molecular biology

RESEARCH SUMMARY
Excitotoxicity is a unique pathophysiological mechanism which is involved in cerebral ischemia, secondary damage in neuronal trauma, and neuronal damage from prolonged seizures. The deleterious effects from excitotoxicity result from calcium entry through a specific glutamate receptor, the N-methyl D-aspartate (NMDA) receptor. NMDA receptor antagonists act both as neuroprotective agents against excitotoxicity and as anticonvulsants in animals, but human clinical trials with the most potent agents have been complicated by side effects including psychosis. Much evidence indicates the presence of multiple types of NMDA receptors in the brain, and evidence from our laboratory suggests that different subtypes play different roles in physiological and excitotoxic processes. If one could develop therapeutic agents which are selective for the subtypes involved in excitotoxicity, one could more readily utilize NMDA receptor antagonists for treatment of human diseases.

We use a systematic approach to examine the subtype specific physiological and pharmacological properties of NMDA receptors. NMDA receptors are created in tissue culture expression systems, and their properties are studied biochemically, pharmacologically and physiologically to correlate receptor properties in these systems with such properties in vivo. We have previously shown that different NMDA receptor subtypes have distinct pharmacologies and produce different changes in intracellular calcium. In the near future we will extend these examinations of subtype specific properties to include the modulation of other intracellular messengers such as nitric oxide and examine the effect of such properties on excitotoxicity. Combined with our studies on the pharmacological specificity of NMDA receptor subtypes, this will facilitate the development of therapeutic agents directed to those NMDA receptors which play crucial roles in excitotoxicity.

Selected Publications

Regner, S.R., Lagedrost, S.J., Plappert, T., Paulsen, E.K., Friedman, L.S., Snyder, M.L., Perlman, S.L., Mathews, K.D., Wilmot, G.R., Schadt, K.A., Sutton, M.S., Lynch, D.R.: Analysis of Echocardiograms in a Large Heterogeneous Cohort of Patients With Friedreich Ataxia. American Journal of Cardiology 109(3): 401-5, Feb 2012

Meier, T, Perlman, S. L., Rummey, C., Coppard, N. J., Lynch, D.R.: Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. Journal of Neurology 259(2): 284-91, Feb 2012

Evans-Galea, M.V., Carrodus, N., Rowley, S.M., Corben, L.A., Tai, G., Saffery, R., Galati, J., Wong, N.C., Craig, J.M., Lynch, D.R., Regner, S., Brocht, A.F.D., Perlman, S.L., Bushara, K.O., Gomez, C.M., Wilmot, G.R., Li, L., Varley, E., Delatycki, M.B., Sarsero, J.P..: FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Annals of Neurology 71(4): 487-97, April 2012.

Singh, P., Doshi, S., Spaethling, J.M., Hockenberry, A.J., Patel, T.P., Geddes-Klein, D.M., Lynch, D.R., Meaney, D.F. : NMDA receptor mechanosensitivity is governed by the C-terminus of the NR2B subunit. Journal of Biological Chemistry 287(6): 4348-59, Feb 2012.

Lynch, DR, Willi, SM, Wilson,RB, Cotticelli, MG, Brigatti, K, Deutsch, EC , Kucheruk, O, Shrader, W., Rioux, P, Miller, G, Hawi, A, Sciascia, T: A0001 in Friedreich ataxia: Biochemical characterization and effects in a clinical trial. Movement Disorders 2012 Notes: in press.

Mahishi, L, Lynch, DR, Ratan, R: MiR-886-3p levels are elevated in Friedreich ataxia. Journal of Neuroscience 2012 Notes: in press.

Friedman, LS, Schadt, KA, Regner, SR, Mark, GE, Lin, KY, Sciascia, T, St John Sutton, M, Willi, S, Lynch, DR: Elevation of Serum Cardiac Troponin I in a Cross-Sectional Cohort of Asymptomatic Subjects with Friedreich Ataxia International Journal of Cardiology 2012 Notes: in press.

Snyder, M., Seyer, L., Lynch, D.R., Resnick, A., Zesiewicz, T. A. : Cardiac Dysfunction Induced by Endocrinopathies in Friedreich’s Ataxia Journal of Child Neurology 2012 Notes: in press.

Hsien-Yang, L., Yong, H., Bruneau, N.,Roll, P., Roberson, E., Hermann, M.,Quinn, E., Maas, J., Edwards, R., Ashizawa, T., Baykan, B., Bhatia, K., Bressman, S., Bruno, M. K., Brunt, E. R., Caraballo, R., Echenne, B., Fejerman, N., Frucht, S., Gurnett, C. A., Hirsch, E., Houlden, H., Jankovic, J., Lee, W. L., Lynch, D. R., Mohamed, S., Müller, U., Nespeca, M. P., Renner, D., Rochette, J., Rudolf, G., Saiki, S., Soong, B.W., Swoboda, K. J., Tucker, S., Wood, N., Hanna, M., Bowcock, A., Szepetowski, P., Fu, Y.H., Ptacek, L.: Mutations in the novel protein PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Reports 1(1): 2-12, December 2011.

Coppola, G., Burnett, R., Perlman, S., Versano, R., Gao, F., Plasterer, H., Rai, M., Saccá, F., Filla, A., Lynch, D.R., Rusche, J.R., Gottesfeld, J.M., Pandolfo, M., Geschwind, D.H. : A gene expression phenotype in lymphocytes from Friedreich Ataxia patients. Annals of Neurology 70(5): 790-804, November 2011.

back to top
Last updated: 05/22/2012
The Trustees of the University of Pennsylvania